stockrowInsulet Corporation
PODD Healthcare Medical Devices
Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024.
- Revenue
- +19.2%
- EPS
- +64.1%
- Free cash flow
- −29.8%
- Total debt
- −5.19%
Quarter to September 2026, against a year earlier
Follow PODD
Alert me
Insulet Corporation (PODD) EPS (diluted)
Insulet Corporation's EPS (diluted) for fiscal 2025 was $3.48, down 39.8% from $5.78 in fiscal 2024. Over the twelve months to 30 September 2026 it was $6.14. Over the past ten years it has ranged from −$1.29 (fiscal 2015) to $5.78 (fiscal 2024); the current reading is higher than 91% of that period. Insulet Corporation ranks 6th of 147 Medical Devices companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $3.48 | (39.79%) |
| FY2024 | $5.78 | 96.60% |
| FY2023 | $2.94 | 4,100.00% |
| FY2022 | $0.07 | (70.83%) |
| FY2021 | $0.24 | 140.00% |
| FY2020 | $0.10 | (47.37%) |
| FY2019 | $0.19 | 280.00% |
| FY2018 | $0.05 | — |
| FY2017 | −$0.46 | — |
| FY2016 | −$0.50 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $2.03 | 48.21% |
| Jun 2026 | $1.37 | 5.38% |
| Mar 2026 | $1.30 | (9.72%) |
| Dec 2025 | $1.44 | 16.13% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| BIO.B Bio-Rad Laboratories, Inc. compare | $37.97 |
| BIO Bio-Rad Laboratories, Inc. compare | $37.97 |
| PODD Insulet Corporation | $6.14 |
| GMED Globus Medical, Inc. compare | $4.07 |
| PEN Penumbra, Inc. compare | $3.97 |
| SNN Smith & Nephew SNATS, Inc. compare | $1.13 |
| TXG 10x Genomics compare | −$0.59 |
| BRKR Bruker Corporation compare | −$1.01 |
| GKOS Glaukos Corporation compare | −$2.94 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on PODD
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement